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Background: In patients with both Type 1 and Type 2 diabetes endogenous insulin secretion falls with time which
changes treatment requirements, however direct measurement of endogenous insulin secretion is rarely performed.
We aimed to assess the impact of endogenous insulin secretion on postprandial glucose increase and the
effectiveness of prandial exogenous insulin.
Methods: We assessed endogenous insulin secretion in 102 participants with insulin treated diabetes (58 Type 1)
following a standardised mixed meal without exogenous insulin. We tested the relationship between endogenous
insulin secretion and post meal hyperglycaemia. In 80 participants treated with fast acting breakfast insulin we
repeated the mixed meal with participants’ usual insulin given and assessed the impact of endogenous insulin
secretion on response to exogenous prandial insulin.
Results: Post meal glucose increment (90 minute - fasting) was inversely correlated with endogenous insulin
secretion (90 minute C-peptide) (Spearman’s r =−0.70, p< 0.001). Similar doses of exogenous prandial insulin
lowered glucose increment more when patients had less endogenous insulin; by 6.4(4.2-11.1) verses 1.2(0.03-2.88)
mmol/L (p< 0.001) for patients in the lowest verses highest tertiles of endogenous insulin.
Conclusions: In insulin treated patients the measurement of endogenous insulin secretion may help predict the
degree of postprandial hyperglycaemia and the likely response to prandial insulin.
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Guidelines for treatment in Type 1 and Type 2 diabetes dif-
fer greatly predominantly reflecting differences in endogen-
ous insulin secretion [1-3]. Within both major subgroups
of diabetes there is both between individual variation and
with time intra-individual reduction in a patient’s endogen-
ous insulin secretion which results in differing treatment
requirements [4-6]. Traditionally, in clinical practice, en-
dogenous insulin secretion is not measured and treatment* Correspondence: angus.jones@pms.ac.uk
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reproduction in any medium, provided the ordecisions are made on the basis of glycaemic control and
clinical diagnosis of diabetes subtype. There is some evi-
dence supporting direct measurement of endogenous insu-
lin secretion to assess the most appropriate treatment for a
patient, particularly in the context of predicting response to
oral therapy [7-19]. Little is known regarding whether
measuring endogenous insulin secretion can assist choice
of insulin regimen.
It is possible to measure endogenous insulin secretion in
clinical practice using C-peptide, which is secreted in equi-
molar amounts to insulin [20]. 90 minute C-peptide in a
formal mixed meal test is a robust assessment of insulin
response in insulin treated patients [21].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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to affect treatment requirements is requirement for
prandial exogenous insulin. Intensive insulin regimens
with prandial rapid or short acting insulin are clearly ap-
propriate in Type 1 diabetes outside the honeymoon
period where there is absolute insulin deficiency [3].
However in Type 2 diabetes where endogenous insulin
secretion is preserved, excellent glycaemic control can
be achieved using basal (intermediate or long acting) in-
sulin without rapid or short acting prandial insulin
[22,23].
We hypothesised that in insulin treated diabetes,
patients with higher endogenous insulin secretion will
have a lower rise in glucose after meals and will respond
less to prandial insulin. We aimed to assess this in a
mixed population of Type 1 and Type 2 diabetes with a
wide spectrum of insulin secretion.
Aims
To assess the relationship between endogenous insulin
secretion as measured by 90 minute post mixed meal
serum C-peptide and:
1. Post-prandial glucose increment (90 minute –
fasting glucose) in a standardised mixed meal test
without concurrent exogenous prandial insulin
2. Treatment response to exogenous prandial insulin as
assessed by change in mixed meal glucose increment
when exogenous prandial insulin is given
Methods
Study participants
We recruited 102 adults with insulin treated diabetes,
HbA1c <86 mmol/mol (10%) and without renal impair-
ment (eGFR> 60mls/min/1.73 m2) from existing research
databases and clinical secondary care, as described previ-
ously [24,25]. 58 had Type 1 diabetes (16 within 3 years of
diagnosis, median (interquartile range, IQR) age of diagno-
sis 20 (14–27), BMI 25 (22–27)), 44 had Type 2 diabetes
(median (IQR) age of diagnosis 55 (47–59), BMI 29(28–36),
classification based on clinical diagnosis from health
records), 60 were male. Median (IQR) age was 57 years
(42–69), diabetes duration 16 years (6–28), BMI kg/m2 27
(24–29) and HbA1c 63 mmol/mol (55–72) (7.9% (7.2-8.7)).
The study was approved by the South West Research Ethics
Committee (UK) and conducted in accordance with the
Declaration of Helsinki. Written informed consent was
obtained from all participants.
Mixed meal tests
All patients underwent a standardised morning mixed
meal test (MMT) without morning insulin. In a subgroup
of 80 patients treated with prandial breakfast insulin (rapid
analogue 61 (4 via insulin pump), rapid analogue/basalmixed 9, human prandial soluble 2, human soluble/basal
mixed 8) a further morning MMT was performed with
participants’ normal morning insulin dose given. Mixed
meal tests were conducted in random order using a
randomization list generated in StatsDirect 4 (StatsDirect
Ltd, UK), between 48 h and 2 weeks apart. In addition all
participants collected a home urine sample 2 hours after
their largest meal for urine C-peptide creatinine ratio
(UCPCR) as described previously [24-26].
Mixed meal test without insulin (MMT)
This was performed according to a standard protocol as
reported previously [21,25]. In brief participants fasted from
midnight without taking their usual morning insulin or
OHA. Capillary glucose was measured pre test and test
rescheduled if <4 or >15 mmol/L (<72 or >270 mg/dl).
Serum C-peptide, creatinine, glucose, and HbA1c were
measured on a fasting sample. Participants consumed a
standardised mixed meal (Ensure Plus HP (Abbott Nutri-
tion, Illinois, USA) 6 ml/kg (maximum 360 ml), content
per 100 ml: carbohydrate 15.9 g, protein 7.9 g, fat 3.3 g,
energy 125 kcal). C-peptide and glucose were measured at
90 minutes post completion of mixed meal.
Mixed meal test with insulin (MMT+ I)
Performed as per mixed meal protocol above except parti-
cipants took their usual morning insulin dose before
ingestion of the mixed meal. Participants were asked not to
correct for hyperglycaemia. Investigators advised a reduced
insulin dose in 9 participants where home breakfast was
judged to contain substantially more carbohydrate than the
mixed meal. Those carbohydrate counting (including insu-
lin pump users) used their normal breakfast insulin to
carbohydrate ratio. Normal basal insulin was continued in
all participants. Oral hypoglycaemic medications were with-
held until completion of the MMT on the morning of both
tests.
Sample analysis
All samples were analysed in the Biochemistry depart-
ment at the Royal Devon & Exeter Hospital, Exeter, UK.
We undertook C-peptide analysis using the routine
automated Roche diagnostics (Manheim, Germany)
E170 immuno-analyser.
Statistical analysis
Data were not normally distributed therefore non paramet-
ric tests were used. We assessed the relationship between
90 minute serum C-peptide (SCP) in MMT and both glu-
cose increment (90 minute glucose minus fasting glucose)
in MMT and decrease in glucose increment with concur-
rent insulin (increment in MMT minus increment in
MMT+ I). We used Spearman’s rank correlation coefficient
to assess correlations. Linear regression analysis was used
ab
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for potential confounders. Residuals were checked to en-
sure model assumptions were met, given the data were not
normally distributed.
In the participants who completed MMT+I data were
split into tertiles of endogenous insulin secretion defined by
90 minute serum C-peptide. We assessed statistical trends
in mixed meal test results and participant characteristics
across tertiles of endogenous insulin secretion using the
Jonckheere test or (for proportions) Chi-squared for trend.
Results
Patients who have less endogenous insulin secretion
have a higher glucose increase after a mixed meal
The glucose increment in a mixed meal, defined as the in-
crease in glucose from fasting to 90 minutes post meal
(90 minute – fasting glucose) was negatively correlated with
90 minute serum C-peptide (SCP) (Spearman’s r =−0.70,
p< 0.001, Figure 1) indicating that the glucose increment
was smaller with higher C-peptide. In line with this, linear
regression showed the association was consistent with a fall
of 2.4 mmol/L glucose for every 1 nmol/L increase in SCP
(B=−2.4 (CI −3.1 to −1.8, p< 0.001)). This was also shown
by analysing glucose response by tertiles of endogenous in-
sulin secretion where glucose increment was greatest in
lower tertiles of endogenous insulin secretion; median
(IQR) glucose increment 11.4 mmol/L (9.4-14.0) tertile 1,
9.0 (6.4-10.5) tertile 2 and 7.0 (4.6-8.0) tertile 3, p< 0.001.
Patients with less endogenous insulin secretion have
greater response to exogenous prandial insulin
To assess the impact of prandial exogenous insulin we
measured the reduction in glucose increment after a
mixed meal when prandial exogenous insulin was givenFigure 1 Relationship between MMT stimulated C-peptide
(nmol/L) and glucose increment (90 minute glucose – fasting
glucose, mmol/L) in MMT without concurrent insulin.
r = Spearmans ro correlation coefficient.(glucose increment in MMT minus glucose increment in
MMT+ I). The reduction in glucose increment with ad-
ministration of prandial exogenous insulin was also
negatively correlated with SCP (r =−0.61, p< 0.001,
n = 80, Figure 2A). Exogenous prandial insulin resulted
in a greater reduction in glucose increment in those with
lower C-peptide; linear regression B was −2.5 (CI −3.4 to
−1.6, p< 0.001) suggesting a fall of 2.5 mmol/L in the
reduction in glucose increment with prandial insulin ad-
ministration for every 1 nmol/L increase in SCP. The re-
lationship persisted after adjusting for age, age of
diagnosis, BMI, gender, fasting glucose and HbA1c
(p = 0.04). Of these clinical variables in multivariable
analysis only SCP and age of diagnosis (p = 0.02) wereFigure 2 a: Scatterplot showing the relationship between MMT
stimulated C-peptide (nmol/L) and reduction in glucose
increment with administration of prandial exogenous insulin.
b: Boxplot showing reduction in MMT glucose increment with
the addition of prandial exogenous insulin by 90 minute post
MMT C-peptide tertile. Horizontal line represents median, box
interquartile range, ‘whiskers’ represent spread of remaining values.
p for trend <0.001.
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ous prandial insulin.
To further assess this relationship we subdivided
our participants by tertiles of endogenous insulin se-
cretion. Characteristics of participants in each tertile
are shown in Table 1 and mixed meal results by ter-
tile in Table 2. Patients in the lowest tertile of en-
dogenous insulin secretion were likely to be
diagnosed younger and have lower BMI, consistent
with a greater proportion having type 1 diabetes, but
had similar HbA1c compared with the other tertiles.
The associated reduction in glucose increment with
prandial exogenous insulin was substantially lower
with increasing C-peptide; median (IQR) 6.4 mmol/L
(4.2-11.1) tertile 1, 4.0 (2.5-7.9) tertile 2 and 1.2
(0.03-2.88) tertile 3 (p< 0.001), Figure 2B. This oc-
curred despite similar insulin doses and glycaemic
control (Table 1).
These associations remain in those with the same type of
diabetes and similar insulin treatment
Our results were not simply due to differences in dia-
betes subtype or prandial exogenous insulin type. In
those treated with rapid analogue prandial insulin
(basal bolus/pump regimen only - analogue mixed in-
sulin excluded, n = 61) the correlation between 90 mi-
nute C-peptide and reduction in glucose increase
with prandial exogenous insulin (r = −0.56, p< 0.001)
and the relationship across tertiles of endogenous in-
sulin secretion (Table 2) were maintained. In those
with the same type of diabetes the correlations (type
1 diabetes r =−0.49 (p< 0.001, n = 54), type 2 diabetes
r =−0.41 (p = 0.037, n = 26)) and the relationship
across tertiles (Table 2) were also maintained. Results
did not differ when analysed by gender.Table 1 Characteristics of participants (median (IQ range)) by
tertile
Tertile 1
(SCP≤ 0.02,n= 27)
Age (years) 53 (42–62)
Age of diagnosis (years) 15 (8–23)
Duration of Diabetes 36 (26–45)
BMI 26 (23–28)
HbA1c (%) 7.9 (7.2-8.7)
HbA1c (mmol/mol) 63 (55–72)
Proportion Type 1 diabetes 93%
Fasting glucose (mmol/L) (Test 1) 10.1(7.9-12.9)
90 Minute post MMT C-peptide (nmol/L) 0.01 (0–0.01)
Prandial (rapid or soluble only*) insulin
dose administered in MMT+I (units)
8 (5–10)
Total daily insulin dose (units) 46 (33–64)
Participants completing both MMT and MMTI only.
* where participant took a mixed morning insulin the rapid/soluble component waFasting serum C-peptide and home post-prandial UCPCR
can be used as the assessment of endogenous insulin
secretion
When insulin secretion was assessed by other measure-
ments similar relationships were seen.
When assessed by the measurement of fasting C-
peptide correlation with postprandial glucose increase was
−0.69 (p< 0.001) and correlation with reduction in glu-
cose increment with exogenous prandial insulin −0.59
(p< 0.001). The values of fasting C-peptide defining ter-
tiles of endogenous insulin secretion were <0.02, 0.02-
0.28 and >0.28 nmol/L. The associated fall in glucose in-
crement with prandial insulin was [median (IQR)]
6.9 mmol/L (4.2-11.5) tertile 1, 3.6 (2.3-7.3) tertile 2 and
1.4 (0.4-3.3) tertile 3 (p< 0.001).
When assessed by the measurement of UCPCR correl-
ation with postprandial glucose increase was −0.59
(p< 0.001) and correlation with reduction in glucose in-
crement with exogenous prandial insulin −0.51
(p< 0.001). The values of home evening meal UCPCR
defining tertiles of endogenous insulin secretion were
<0.03, 0.03-0.73 and >0.73 nmol/mmol. The associated
fall in glucose increment with prandial insulin was
[median (IQR)] 6.4 mmol/L (4.1-9.4) tertile 1, 4.0 (1.3-
7.9) tertile 2 and 2.0 (0.5-3.3) tertile 3 (p< 0.001).
Discussion
We have shown that patients with less endogenous insu-
lin secretion have greater post meal hyperglycaemia and
greater response to prandial exogenous insulin.
In our study of insulin treated patients with Type 1
and Type 2 diabetes postprandial hyperglycaemia is in-
versely related to endogenous insulin secretion. This is
consistent with previous research in non insulin treated
Type 2 diabetes has shown that those with low insulin90 minute MMT stimulated C-peptide (SCP, nmol/L)
Tertile 2
(SCP 0.02-0.8, n = 27)
Tertile 3
(SCP≥ 0.8, n = 26)
p for trend
42 (30–64) 62 (37–71) 0.70
27 (21–44) 50 (28–59) <0.001
16 (3–21) 10 (2–15) <0.001
25 (23–29) 29 (25–37) 0.013
7.7 (7.0-8.7) 7.9 (7.4-8.7) 0.57
60 (53–71) 63 (57–72) 0.57
78% 31% <0.001
8.8 (6.4-12.8) 8.4 (7.0-10.5) 0.064
0.40 (0.23-0.65) 1.79 (1.12-2.30) <0.001
8 (6–12) 6.3 (4.8-12.3) 0.98
42 (28–62) 45 (26–88) 0.90
s calculated.
Table 2 Mixed meal test results (median (IQ range)) by 90 minute MMT stimulated C-peptide (SCP, nmol/L) tertile
Tertile 1
(SCP≤ 0.02,n = 27)
Tertile 2
(SCP 0.02-0.8, n = 27)
Tertile 3
(SCP≥ 0.8, n = 26)
p for trend
Glucose increment in MMT (without insulin, mmol/L) 10.6 (9.0-13.7) 9.9 (8.2-11.0) 7.1 (4.4-8.9) <0.001
Glucose increment in MMT+I (insulin given, mmol/L) 4.3 (0.4-8.8) 4.4 (2.2-4.4) 5.2 (3.6-6.4) 0.45
Reduction in glucose increment when
prandial insulin given (mmol/L): all participants (n = 80)
6.4 (4.2-11.1) 4.0 (2.5-7.9) 1.2 (0.03-2.88) <0.001
Reduction in glucose increment when
prandial insulin given (mmol/L): Rapid analogue
insulin only* (n = 61):
6.7 (4.3-11.2) 4.0 (2.3-7.9) 1.4 (1.8-3.0) <0.001
Reduction in glucose increment when
prandial insulin given (mmol/L): Type 1 only (n = 54)
6.9 (4.2-11.3) 4.0 (2.4-7.8) 1.9 (0.3-3.5) 0.002
Reduction in glucose increment when
prandial insulin given (mmol/L): Type 2 only (n = 26):
5.1 (4.2-6) 4.5 (2.4-9.2), 1.1 (−0.3-2.4) 0.006
Participants completing both MMT and MMTI only.
*excluding premixed insulin.
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cose tolerance test and higher glycaemic variability
[27,28]. In Type 1 diabetes a reduction in glycaemic vari-
ability with restoration of even small amounts of residual
insulin secretion has been demonstrated after islet trans-
plantation [29].
To our knowledge this is the first study to examine
the relationship between endogenous insulin secretion
and the impact of prandial exogenous insulin adminis-
tration. We showed that the glucose response to exogen-
ous prandial insulin was greatest in those with the
lowest endogenous insulin secretion. In those with the
highest endogenous insulin secretion concurrent pran-
dial exogenous insulin had little effect on glucose re-
sponse despite similar insulin doses and glycaemic
control. A probable explanation is that those with high
endogenous insulin secretion are exposed to their own
endogenous prandial insulin therefore exogenous pran-
dial insulin may be only a small proportion of their total
prandial insulin exposure. This is in contrast to those
with little endogenous insulin secretion where exogen-
ous insulin makes up their entire prandial insulin expos-
ure. In addition the similar exogenous insulin doses and
glycaemic control across tertiles of endogenous insulin
secretion mean insulin resistance is likely to be higher in
those with preserved insulin secretion.
Our findings have potential practical implications for
the management of diabetes. Patients with Type 2 diabetes
progressively lose their beta-cell function over time lead-
ing to increased treatment requirements[6]. Rates of pro-
gression vary widely and progression to severe insulin
deficiency may occur rapidly where a patient with LADA
or Type 1 diabetes has been misclassified as Type 2
[30,31]. A large proportion of patients with Type 2 dia-
betes will eventually require insulin. While background in-
sulin alone may achieve initial glycaemic control many
patients progress to prandial insulin treatment. The deci-
sion when to change to prandial insulin is not well definedand endogenous insulin secretion is rarely measured[32].
Our work suggests that prandial insulin will be most ef-
fective when patients have a lower level of endogenous
insulin as defined by a C-peptide below the top tertile of
our participants; 90 minute post MMT C-peptide
<0.8 nmol/L: fasting C peptide <0.29 nmol/L, or UCPCR
2 hours post home evening meal <0.73 nmol/mmol. Pran-
dial fast acting exogenous insulin may have little impact
on post meal hyperglycaemia above these levels. Assess-
ment of endogenous insulin secretion could also poten-
tially assist in decisions on rationalising a patient’s insulin
regimen, for example where there are potential difficulties
with administering multiple insulin doses or where adher-
ence is thought to be poor a move to once or twice daily
basal insulin may be justified where endogenous insulin
secretion is preserved.
Limitations of our study include that we have recruited
participants with a mixture of Type 1 and Type 2 dia-
betes and that differences seen may reflect differences in
insulin secretion between the two diabetes subtypes.
However the relationships seen, although weaker,
remains when analysing our results by type of diabetes
suggesting the relationship between insulin secretion
and glucose response is not due to differences between
diabetes subtypes alone. It is possible that results could
have been influenced by differences in participant’s oral
hypoglycaemic agents. While diabetes treatments were
withheld on the morning of mixed meal tests, residual
levels of treatment taken the previous day could poten-
tially still affect both glucose and C-peptide. However
this is unlikely to systematically differ between mixed
meal tests (which were conducted in random order) and
a longer period without medication might have made
results less applicable to clinical practice.
A further potential limitation is that our marker of insulin
secretion (90 minute post MMT C-peptide) and measure
of post meal glucose increase (glucose increase from 0 to
90 minutes in the MMT) were measured within the same
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similar results when using fasting C-peptide and UCPCR
(measured on a separate occasion) as markers of insulin se-
cretion. The MMT, while well established and likely more
reproducible than a conventional meal, may not be a nor-
mal physiological stimulus. The more rapid absorption of a
liquid meal could lead to an earlier and greater glucose
peak than a non liquid meal with the same carbohydrate
content. In addition a standardised meal may not reflect a
person’s normal intake. The liquid meal given is likely to
have higher carbohydrate content than many participants
normal breakfast (the carbohydrate content of our mixed
meal was 57 g in those >60 kg, equivalent to 3–4 pieces of
toast).
While we have shown a clear relationship between insulin
secretion and effectiveness of fast acting (prandial) exogen-
ous insulin during a mixed meal test further studies are
needed to assess whether C-peptide could be a clinically
useful measure to assist choice of insulin regimen. It may
be that direct measurement of insulin secretion may assist
clinical decisions on optimal insulin treatment. While a for-
mal mixed meal test is unlikely to be an option in main-
stream clinical practice the association was preserved using
fasting C-peptide and post home meal UCPCR which may
be more applicable to clinical practice [26].Conclusion
Endogenous insulin secretion is predictive of postprandial
hyperglycaemia and response to prandial exogenous insulin.
The measurement of endogenous insulin secretion may be
a helpful guide to insulin therapy.
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